Physician profile
Kenneth E Elek
NPI 1912995267
$543.49
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.40 · 2020: $74.63 · 2021: $163 · 2022: $235.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $64.71 | 2021-2022 | |
| Abbvie INC. | $60.09 | 2021 | |
| Novo Nordisk INC | $57.44 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $55.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.31 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.07 | 2022 | |
| Genentech USA, INC. | $43.58 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.33 | 2021-2022 | |
| Amgen INC. | $37.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.28 | 2021-2022 | |
| Amarin Pharma, INC. | $22.79 | 2020 | |
| Abbott Laboratories | $14.67 | 2021 | |
| Lilly USA, LLC | $11.77 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Elek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.